Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Neurology. 2007 May 1;68(18):1524-8.

Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis.

Author information

  • 1Department of Neurology, University of Rochester Medical Center, Rochester, NY 14620, USA. ray.dorsey@ctcc.rochester.edu

Abstract

Using published data, we quantified the risk and benefits of natalizumab in relapsing multiple sclerosis using quality-adjusted life years (QALYs) as a metric. Over the first 2 years of therapy, the negative health effects from progressive multifocal leukoencephalopathy were small (loss of 0.001 QALYs) relative to the positive effects on relapses and disability resulting in 0.033 QALYs (12 quality-adjusted days) gained. For context, we performed an analogous calculation for interferon beta-1a, which also had a net health benefit of 0.033 QALYs (12 quality-adjusted days).

PMID:
17470756
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk